AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies January 18, 2024
Enrollment opens for Ph 1b/2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer January 18, 2024
First Dose Cohort in Ph 1 Trial of BP1002 to Treat R/R Lymphoma and R/R CLL Patients completed January 18, 2024
First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer January 18, 2024
